India’s pharmaceutical sector has quietly transitioned from being the “world’s generics factory” to becoming one of the most strategic and future-ready life sciences ecosystems globally. Today, the country stands among the top ten most attractive destinations for global pharma investment, exporting to 200+ nations — including the world’s most regulated markets: the US, Western Europe, Japan, and Australia.
India already commands 20% of the global generics market, and the industry is now targeting ₹11,08,380 crore (US$130 billion) in size by 2030. Biotechnology, running in parallel, is projected to reach ₹25,57,800 crore (US$300 billion) by 2030 and US$450 billion by 2047.

With 3,000+ pharma companies, ~10,500 manufacturing units, and a globally integrated supply chain, India ranks 3rd worldwide in pharmaceutical production by volume and 14th by value. The sector’s export engine remains strong —
₹2,59,658 crore (US$30.38 billion) in FY25 and ₹2,43,119 crore (US$27.82 billion) in FY24.

India’s domestic pharma market stands at ₹4,70,085 crore (US$55 billion), with exports contributing over US$25 billion. Notably, 1 out of every 5 generic drugs exported globally originates in India, supporting almost 160 crore people — 20% of the world’s population.

The AI and GenAI Revolution: The Sector’s New Growth Curve

The biggest structural shift underway is digital.
Across the pharma value chain, AI adoption is accelerating:

• 50% of Indian pharma companies are already experimenting with AI
• 25% have GenAI live in production
• Resulting in 30–40% productivity gains in sales, supply chain, and manufacturing

1. Drug Discovery & Development

• AI-driven molecule prediction
• Rapid drug repurposing
• Faster clinical trial design and patient matching
  Impact: Shorter R&D cycles, multi-year cost savings.

2. Manufacturing & Operations

• Predictive maintenance
• Computer-vision-led quality control
• Process optimisation at scale
  Impact: EY reports 35–40% gains in operational and supply chain efficiency.

3. Regulatory & Compliance

• Automated dossier creation
• AI-assisted documentation for FDA/EMA/CDSCO
  Impact: Faster submissions and accelerated market access.

4. Sales & Marketing

• AI-based prescriber segmentation
• GenAI copilots for medical reps
• Market demand forecasting
  Impact: 35% uplift in sales productivity.

5. Supply Chain & Logistics

• Forecast-based inventory planning
• Cold-chain monitoring
• Real-time shipment visibility
  Impact: Lower wastage, higher reliability.

6. Pharmacovigilance

• AI-powered adverse event detection
• Automated case processing
  Impact: Stronger patient safety and regulatory compliance.

Policy Tailwinds Strengthening the Sector

The government has reinforced the sector through major initiatives:

PLI Scheme

• ₹15,000 crore (US$2.04 billion) from 2020–21 to 2028–29
• Incentivising API, KSM, and advanced formulations
• ₹604 crore disbursed in H1 FY25

Strengthening of Pharmaceutical Industry (SPI)

• ₹500 crore (US$60.6 million) to support MSME clusters, quality, and sustainability

Pradhan Mantri Bhartiya Jan Aushadhi Kendras

• Targeting 10,500 stores by March 2025
• Offering 1,451 drugs and 240 surgical items at affordable pricing

India’s Pharma and Biotech: Positioned for Global Dominance

• One of the top 12 biotech destinations globally
• 3rd largest biotech hub in Asia-Pacific
• Bioeconomy valued at US$137 billion (2022); targeting US$300 billion by 2030

With strong manufacturing depth, scientific talent, regulatory confidence, and a fast-maturing AI ecosystem, India’s pharmaceutical and biotech sectors are entering their most transformative decade.

This is not just a manufacturing story — it is a strategic, technology-powered healthcare revolution shaping global outcomes.

‍